-

Tandem Diabetes Care to Announce Second Quarter 2021 Financial Results on August 4, 2021

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2021 results after the financial markets close on Wednesday, August 4, 2021. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2021 financial and operating results.

Conference Call/Webcast Details:
Date:
August 4, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 6897987
Webcast Link: https://edge.media-server.com/mmc/p/ttkpgjat

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

Tandem Diabetes Care, Inc.

NASDAQ:TNDM

Release Versions
$Cashtags

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care, Inc.

Tandem Diabetes Care Announces First Quarter 2026 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a global insulin delivery and diabetes technology company, today reported its financial results for the quarter ended March 31, 2026 and reaffirmed financial guidance for the year ending December 31, 2026. First Quarter 2026 Financial and Strategic Highlights Achieved record first quarter pump shipments, sales and gross margin: Shipments of more than 29,000 pumps worldwide, including 19,000 pumps in the United States Sales o...

Tandem Diabetes Care Announces Upcoming Conference Presentations

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that management will present a company update at the following investor conferences: BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026 at 5:20 pm Eastern Time (2:20 pm Pacific Time), and Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 3:20 pm Eastern Time (12:20 pm Pacific Time). The presentations...

Tandem Diabetes Care’s Control-IQ+ Automated Insulin Delivery Technology Now FDA Cleared for Pregnancy in Type 1 Diabetes

SAN DIEGO--(BUSINESS WIRE)--FDA clears Tandem Diabetes Care's Control-IQ+ automated insulin delivery technology for use in pregnancy for people with type 1 diabetes....
Back to Newsroom